| Name | Title | Contact Details |
|---|---|---|
Libbie Mansell |
Chief Regulatory and Quality Officer | Profile |
genscript is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company`s proprietary platforms have already identified one potential new target for treating Parkinson`s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer`s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.
General Automation Lab Technologies (GALT), a San Francisco-based life science company, is developing advanced products to help researchers and companies cultivate and study bacteria and other microbes.
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.
zacharon is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.